What exactly changed in the MDT analyst rating on February 03, 2026?

Leerink Partners **maintained** an Outperform rating for Medtronic plc on February 03, 2026. The note reaffirmed MDT as a Top Pick for 2026 and did not include a new price target.

How should investors interpret a maintained Outperform for MDT?

A maintained Outperform signals continued analyst conviction that MDT will outperform peers. Investors should combine this view with valuation, earnings outlook, and their time horizon before trading.

Did Leerink publish a new MDT price target with this rating?

No. Leerink’s February 03, 2026 commentary reaffirmed Outperform but did not list a new MDT price target in the published note on StreetInsider. Check the full note for details.

What is Meyka AI’s current view on MDT?

Meyka AI rates MDT with a grade of B+. This grade weighs S&P 500 comparison, sector strength, growth, metrics, and analyst consensus. These grades are not guarantees and we are not financial advisors.

Analyst Ratings

Leerink Maintains Outperform on MDT Medtronic plc Feb 2026

ByDanny Kontos February 4, 2026

Leerink Partners on February 03, 2026 maintained an Outperform view on Medtronic plc (MDT), a clear MDT analyst rating update from a notable healthcare specialist. This note, published at 01:11 PM, keeps Medtronic on Leerink’s 2026 Top Picks list and contains no new price target. The market moved slightly on the note, with a -0.27% change equivalent to $-0.28. We review the rating, what it means for investors, and how this fits into historical analyst coverage.